A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment

Antiviral Therapy

Volumn 12, Issue 5, 2007, Pages 761-768

  Karatayli, Ersin ^a   Karayalçin, Selim ^a   Karaaslan, Hayri ^b   Kayhan, Handan ^a   Türkyilmaz, A Resat ^a   Sahin, Fikret ^a   Yurdaydin, Cihan ^a   Bozdayi, A Mithat ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CLEVUDINE; EMTRICITABINE; INTERFERON; LAMIVUDINE; MEMBRANE ANTIGEN; NUCLEOSIDE ANALOG; TENOFOVIR;

ARTICLE; CELL LINE; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; GENE MUTATION; HEPATITIS B; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD;

ADENINE; ADULT; ARABINOFURANOSYLURACIL; BASE SEQUENCE; CELL LINE, TUMOR; CLONING, MOLECULAR; DEOXYCYTIDINE; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 34547792213     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Zoulim, F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antivir Res 2004; 64:1-15.
2. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758.
3. Severini A, Liu XY, Wilson JS, Tyrrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′- dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995; 39:1430-1435.
4. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
5. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19:1276-1282.
6. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
7. Jardi R, Buti M, Rodriguez-Frias F, et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999; 83:181-187.
8. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003; 10:256-265.
9. Bozdayi AM, Eyigun CP, Türkyilmaz AR, Avci IY, Pahsa A, Yurdaydin C. A novel pattern (sW195A) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and succesful treatment with adefovir dipivoxil. J Clin Virol 2004; 31:76-77.
10. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38:702-707.
11. Delaney WE 4th, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77:11833-11841
12. Balzarini J, Naesens L, Herdewijn P, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A 1989; 86:332-336.
13. De Clercq E. New acquisitions in the development of anti-HIV agents. Antiviral Res 1989; 12:1-19.
14. Lin JC, De Clercq E, Pagano JS. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother 1987; 31:1431-1433.
15. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669-1673.
16. Gilson RJC, Chopra KB, Newell AM, et al. A placebo-controlled Phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6:387-395.
17. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
19. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006; 20:2229-2231
20. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354:1807-1812.
21. Lindh M, Gonzalez JE, Norkrans G, Horal P. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J Virol Met 1998; 72:163-174.
22. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
23. Da Silva LC, da Fonseca LE, Carrilho FJ, Alves VA, Sitnik R, Pinho JR. Predictive factors for response to lamivudine in chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2000; 42:189-196
24. Yang H, Westland C, Xiong S, Delaney WE 4th. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004; 61:27-36.
25. Bozkaya H, Yurdaydin C, Idilman R, et al. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antivir Ther 2005; 10:319-325.
26. Seta T, Yokosuka O, Imazeki F, Tagawa M, Saisho H. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000; 60:8-16.
27. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670-1677.
28. Pai SB, Bozdayi AM, Pai RB, et al. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 2005; 49:2618-2624.
29. Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6- diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L- arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45:2495-2501.
30. Delaney WE 4th, Edwards R, Colledge D, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45:1705-1713.
31. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669-1673.
32. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44:703-712.
33. Fu L, Cheng YC. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother 2000; 44:3402-3407.
34. Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46:2525-2532.
35. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36:710-722.
36. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-1398.
37. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9:353-363.
38. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine resistant mutants of hepadnaviruses. Hepatology 2002; 36:710-722.
39. Kukhanova M, Lin ZY, Yas'co M, Cheng YC. Unique inhibitory effect of 1-(2′-deoxy-2′-fluoro-β-L-arabinofuranosyl) -5-methyluracil 5′-triphosphate on Epstein-Barr virus and human DNA polymerases. Biochem Pharmacol 1998; 55:1181-1187.
40. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25:9-19.